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Background: Oral factor Xa inhibitor rivaroxaban (Riva) was shown to be superior to enoxaparin (Enox) for prevention of venous thromboembolism 
(VTE) after hip or knee arthroplasty in 4 RECORD trials. However, the benefit was driven by asymptomatic VTE, a surrogate endpoint of questionable 
clinical relevance.
Objective: A reanalysis of RECORD trials with emphasis on clinically relevant endpoints.
Methods: Symptomatic VTE or death and major or non-major clinically relevant bleeding were assessed. We analyzed data with and without pooling 
RECORD 2 and 3 where suboptimal treatment duration and dose of Enox potentially biased the results in favor of Riva. Clinically important benefit 
was inferred when the NNH exceeded the NNT.
Results (Table): 117 of 583 total VTE were symptomatic VTE or death (20%) and 355 of 835 bleeding events were clinically relevant (43%). Pooled 
analysis revealed a 0.76% absolute or 57% relative reduction in VTE or death with Riva, driven primarily by RECORD 2 and 3. In contrast, a 0.64% 
absolute or 25% relative increase in bleeding was observed with Riva acoss trials. The pooled 1 to 4 NNT for both efficacy endpoints (132 and 156) 
equaled the NNH (157). In contrast, the pooled 1 and 4 NNT (249 and 311) exceeded the NNH (144).
Conclusions: The benefit-risk profile for Riva is balanced when data from all 4 studies are pooled and unfavorable when data from 1 and 4 trials 
are pooled. These results challenge the claim that the benefit of Riva outweighs its risk compared to Enox after hip or knee arthroplasty. 
Trial Rivaroxaban Enoxaparin ARD NNT or NNH (-) Reletive risk (95% CI)
Symptomatic VTE or death
RECORD 1 10/2209 (0.45%) 15/2224 (0.67%) 0.22% 451 0.7 (0.3-1.5)
RECORD 2 5/1228 (0.41%) 20/1229 (1.63%) 1.22% 82 0.2 (0.1-0.7)
RECORD 3 8/1220 (0.66%) 26/1239 (2.10%) 1.44% 69 0.3 (0.1-0.7)
RECORD 4 12/1526 (0.79%) 21/1508 (1.39%) 0.61% 165 0.6 (0.3-1.2)
Pooled 1 to 4 35/6183 (0.57%) 82/6200 (1.32%) 0.76% 132 0.43 (0.29-0.63)
Pooled 1 & 4 22/3735 (0.59%) 37/3732 (0.99%) 0.40% 249 0.59 (0.35-1.01)
Symptomatic VTE
Pooled 1 to 4 28/6183 (0.45%) 68/6200 (1.09%) 0.64% 156 0.41(0.27-0.64)
Pooled 1 & 4 17/3735 (0.46%) 29/3732 (0.78%) 0.32% 311 0.59 (0.32-1.06)
Major bleeding or non-major clinically relevant bleeding
RECORD 1 70/2209 (3.17%) 56/2224 (2.52%) -0.65% -154 1.3 (0.9-1.8)
RECORD 2 41/1228 (3.34%) 34/1229 (2.77%) -0.57% -175 1.2 (0.8-1.9)
RECORD 3 40/1220 (3.28%) 34/1239 (2.74%) -0.53% -187 1.2 (0.8-1.9)
RECORD 4 46/1526 (3.01%) 34/1508 (2.25%) -0.76% -132 1.3 (0.9-2.1)
Pooled 1 to 4 197/6183 (3.19%) 158/6200 (2.55%) -0.64% -157 1.25 (1.02-1.54)
Pooled 1 & 4 116/3735 (3.11%) 90/3732 (2.41%) -0.69% -144 1.29 (0.98-1.69)
